Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

That increase has boosted valuations, as the price-to-sales (P/S) ratio of 19 indicates that the stock is not cheap. Still, considering that ServiceNow's average P/S ratio over the last five years is ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

So as a company, whether it's in the U.S. or international, we've made great progress. And then I would think to address your question, going back to New York City in 2019, we certainly made steady ...